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Tyrosinemia is a rare genetic disease caused by mutations on genes that codify enzymes responsible for
tyrosine metabolism. Considering that tyrosinemics patients usually present symptoms associated with
central nervous system alterations that ranges from slight decreases in intelligence to severe mental
retardation, we decided to investigate whether acute and chronic administration of L-tyrosine in rats
would affect acetylcholinesterase mRNA expression and enzymatic activity during their development.
In our acute protocol, Wistar rats (10 and 30 days old) were killed one hour after a single intraperitoneal
L-tyrosine injection (500 mg/kg) or saline. Chronic administration consisted of L-tyrosine (500 mg/kg) or
saline injections 12 h apart for 24 days in Wistar rats (7 days old) and rats were killed 12 h after last injec-
tion. Acetylcholinesterase activity was measured by Ellman’s method and acetylcholinesterase expres-
sion was carried out by a semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR)
assay. We observed that acute (10 and 30 days old rats) and chronic L-tyrosine administration increased
acetylcholinesterase activity in serum and all tested brain areas (hippocampus, striatum and cerebral cor-
tex) when compared to control group. Moreover, there was a signiﬁcant decrease in mRNA levels of ace-
tylcholinesterase in hippocampus was observed after acute protocol (10 and 30 days old rats) and in
striatum after chronic protocol. In case these alterations also occur in the brain of the patients, our results
may explain, at least in part, the neurological sequelae associated with high plasma concentrations of
tyrosine seen in patients affected by tyrosinemia type II.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Tyrosine is an amino acid degraded primarily in the hepatocytes
being both glucogenic and ketogenic. Under most circumstances,
tyrosine degradation rate is determined by tyrosine aminotransfer-
ase activity (Held, 2006) but deﬁciency of any of the catabolic en-
zymes involved will lead to an accumulation of tyrosine in tissues,
cerebrospinal ﬂuid (CSF), blood and urine leading to formation of
characteristic crystals (Scott, 2006). Tyrosinemia is a rare disease
and caused by genetic variants in one of the genes that codify en-
zyme responsible for tyrosine metabolism (Nakamura et al., 2007).
In humans, three distinct autosomal recessive diseases of tyrosinenergética, Universidade do
ciúma 88806-000, SC, Brazil.
ck).
sevier OA license.catabolism have been identiﬁed: tyrosinemia type I (deﬁciency of
fumarylacetoacetate hydrolase), tyrosinemia type II (deﬁciency
of tyrosine aminotransferase) and tyrosinemia type III (deﬁciency
of 4-hydroxyphenylpyruvate dioxygenase) (Held, 2006; Mitchell
et al., 2001).
Tyrosinemia type II is characterized by the highest level of tyro-
sine among all tyrosinemias. Although brain tyrosine concentra-
tion in type II patients is not known, it has been reported plasma
tyrosine levels exceeding 1000 mM in untreated type II patients
(Scott, 2006) with results ranging from 370 to 3420 mM (normal
<90 mM) along with some tyrosine derivatives accumulation (4-
hydroxyphenylpyruvic acid, 4-hydroxyphenyllactic acid and 4-
hydroxyphenylacetic acid). Eyes, skin and nervous system are the
main organs affected by tyrosine aminotransferase deﬁciency
(Held, 2006; Goldsmith et al., 1973; Macsai et al., 2001; Mitchell
et al., 2001; Rabinowitz et al., 1995; Valikhani et al., 2005). Involve-
ment of the central nervous system is variable and ranges from
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may be associated with microcephaly, tremor, ataxia, self-mutilat-
ing behavior, ﬁne motor coordination disturbances, language deﬁ-
cits, and convulsions (Goldsmith et al., 1973; Lemonnier et al.,
1979; Macsai et al., 2001; Mitchell et al., 2001; Rabinowitz et al.,
1995; Valikhani et al., 2005). Little is known regarding tyrosine-
induced molecular alterations that may explain these symptoms.
Alterations during neurodevelopment are expected in patients
with type II tyrosinemia. L-Tyrosine can interfere in the develop-
ment of cholinergic system through the dopaminergic system. This
interferencemayoccur because L-tyrosine is responsible for the syn-
theses of catecholamines (Mitchell et al., 2001). According with the
literature, the cholinergic system interacts with dopaminergic sys-
tem, as a modulatory system. During neural development a correct
and organized set of neurotransmitters and neuromodulators is
essential to promote the stimuli needed affecting synaptic contact
formation, synapses maturation and structural reﬁnement of con-
nectivity (Zhang and Poo, 2001). Acetylcholine (Ach) is one of the
major neurotransmitters involved in cortical activation, attention,
memory, learning, pain, control of motor tone, locomotion and con-
trol of autonomic functions (Herlenius and Lagercrantz, 2004). Ach
acts thought speciﬁc receptorswhichare clustered in thepostsynap-
tic membrane. Central cholinergic deﬁcits are strongly related to
neurodegenerative diseases, such as Alzheimer’s and Parkinson’s
diseases (Soreq and Seidman, 2001; Oda, 1999).
Cholinergic transmission is mainly terminated by acetylcholin-
esterase (AChE: EC 3.1.1.7), a fast serine hydrolase enzyme that
cleaves Ach into choline and acetate (Soreq and Seidman, 2001).
It has been described that AChE is also involved with glial activa-
tion, cerebral blood ﬂux, amyloid cascade, tau phosphorylation,
as well as an action as adhesion protein in synaptic development
and maintenance (Ballard et al., 2005). Considering that tyrosine-
mia patients usually present symptoms associated with distur-
bances of the central nervous system and AChE plays a major
role regulating cholinergic functions, we have investigated
whether L-tyrosine administration would affect AChE mRNA
expression and its activity in brain and serum of rats during their
development.
2. Material and methods
2.1. Animals and reagents
Sixty Wistar rats males of different litter were obtained from
Central Animal House of Universidade do Extremo Sul Catarinense.
They were caged in group of ﬁve with free access to food and water
and were maintained on a 12-h light–dark cycle (lights on
7:00 am) at a temperature of 23 ± 1 C. All experimental proce-
dures were carried out in accordance with the National Institutes
of Health Guide for the Care and Use of Laboratory Animals and
the Brazilian Society for Neuroscience and Behavior recommenda-
tions for animal care with the approval of the Ethics Committee
from Universidade do Extremo Sul Catarinense (protocol number
42/2010). All chemical were purchased from Sigma Chemicol Co.,
St. Louis, MO, USA. L-Tyrosine was dissolved in saline solution
(pH was adjusted to 7.4).
2.2. Administration of L-tyrosine
In our acute protocol, forty Wistar rats males (10 and 30 days
old) were killed one hour after a single intraperitoneal L-tyrosine
injection (500 mg/kg) or saline (n = 10 each group). Chronic admin-
istration consisted of L-tyrosine (500 mg/kg) or saline injections
(n = 10 each group) 12 h apart for 24 days in twenty Wistar rats
males (7 days old) and rats were killed 12 h after last injection. This
dose was chosen in order to obtain L-tyrosine concentrations about10 times normal one hour after administration (Morre et al., 1980;
Bongiovanni et al., 2003) which are similar variations of plasma
L-tyrosine concentration observed in patients affected by tyrosine-
mia type II (Mitchell et al., 2001). Rats’ age was selected consider-
ing Ach metabolism in rodents. Ach reaches mature levels around
8 weeks after birth in rodent brain and its degradation rate in-
creases in a time-dependent manner after birth attaining stability
at 21 days of neonatal life (Berger-Sweeney and Hohmann, 1997;
Lassiter et al., 1998; Mortensen et al., 1998). Serum and brain were
collected and hippocampus, striatum and cerebral cortex were
dissected (Llesuy et al., 1985). The same rats were used for both
measurements: AChE activity and analysis of gene expression by
semi-quantitative RT-PCR.
2.3. Acetylcholinesterase activity
For AChE assay, hippocampus, striatum and cerebral cortex
were homogenized in 10 volumes 100 mM potassium-phosphate
buffer (pH 7.5) and centrifuged at 1000g for 10 min. The superna-
tants were used for AChE activity analysis according to the method
of Ellman et al. (1961). The reaction mixture (2 ml ﬁnal volume)
contained 100 mM potassium-phosphate buffer, pH 7.5 and
1 mM 5,50-dithiobisnitrobenzoic acid (DTNB). The method is based
on the formation of the yellow anion, 5,50-dithio-bis-acid-
nitrobenzoic, measured by absorbance at 412 nm during 2-min
incubation at 25 C. The enzyme (40–50 lg of protein) was pre-
incubated for 2 min. The reaction was initiated by adding 0.8 mM
acetylthiocholine iodide (AcSCh). All samples were run in duplicate
or triplicate and the enzyme activity were expressed in lmol AcS-
Ch/h/mg of protein. Protein was measured by the method of Lowry
et al. (1951)) using bovine serum albumin as standard.
2.4. Analysis of gene expression by semi-quantitative RT-PCR
The analysis of ache mRNA expression was carried out by a
semi-quantitative reverse transcriptase polymerase chain reaction
(RT-PCR) assay. Striatum, hippocampus and cerebral cortex were
dissected under sterile conditions followed by a total RNA extrac-
tion using TRIzol Reagente (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer instructions. RNA was quantiﬁed by
spectrophotometry and cDNA species were synthesized with Im-
Prom-II™ Reverse Transcription System (Promega) following the
suppliers. PCR reactions for ache and b-actin genes (Keseler et al.,
2005) were performed using 0.1 lM primers (ache forward: 50-
GAC TGC CTT TAT CTT AAT GTG-30 and reverse: 50-CGG CTG ATG
AGA GAT TCA TTG-30; b-actin forward 50-TAT GCC AAC ACA GTG
CTG TCT GG-30; and reverse 50-TAC TCC TGC TTC CTG ATC CAC
AT-30) 0.2 lM dNTP, 2 mM MgCl2 and 0.1 U Platinum Taq DNA
polymerase (Invitrogen) in a total volume of 25 lL for ache and
20 lL for b-actin. The following conditions were used for the PCR
reactions: 1 min at 94 C; 1 min for annealing temperature (54 C
for b-actin and 55 C for ache) and 1 min at 72 C for 35 cycles.
Post-extension at 72 C was performed for 10 min. For each set of
PCR reactions, negative control was included. PCR products (ache:
785 bp, b-actin: 210 bp) were analyzed on 1.5% agarose gel, con-
taining GelRed (Biotium) and visualized under ultraviolet light.
The Low DNA Mass Ladder (Invitrogen) was used as molecular
marker and normalization was performed employing b-actin as a
constitutive gene.
2.5. Statistical analysis
Results are presented as means ± standard deviation. Assays
were performed in duplicate and mean was used for statistical
analysis. Tests for determination of normality and equal variances
were performed to examine whether our data qualiﬁed for para-
Fig. 1. Effect of acute administration of L-tyrosine on acetylcholinesterase activity
(lmol of ACSch per hour per mg protein) in hippocampus, striatum, cerebral cortex
and serum of 10-day-old rats (A), 30-day-old rats (B), and effect of chronic
administration of L-tyrosine on AChE activity in hippocampus, striatum, cerebral
cortex and serum of rats (C). Data are expressed as mean ± standard deviation
(mean ± SD of 5–6 animals per group). Different from control, ⁄p < 0.05 (Student’s t
test).
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Wilk, p > 0.05) with equal variances among samples (equal
variances test, p > 0.05). Thus, the Student’s t-test was used for
comparison of two means. Differences between the groups were
rated signiﬁcant at p < 0.05. All analyses were carried out in an
IBM-compatible PC computer using the Statistical Package for the
Social Sciences (SPSS) software.
3. Results
We ﬁrst examined acute and chronic administration of L-tyro-
sine effects on the AChE activity and after the AChE activity regu-
lation, which could be a consequence of transcriptional control
and/or posttranslational modiﬁcations. In the acute administra-
tions of L-tyrosine in 10 and 30-day-old rats, increased AChE activ-
ity in serum and all evaluated brain areas when compared to
control group (Fig. 1A and Fig. 1B). There was a signiﬁcant decrease
in mRNA levels of AChE only in hippocampus after acute adminis-
tration in both ages (Fig. 2A and B). Moreover, chronic administra-
tion of L-tyrosine has also increased AChE in serum and all
analyzed brain areas (Fig. 1C). The mRNA levels of AChE have been
decreased only in striatum (Fig. 2C).
4. Discussion
Our results indicate that L-tyrosine administration increases
AChE activity in cerebral cortex, striatum, hippocampus and serum
while decreases ache mRNA expression in hippocampus and stria-
tum after acute and chronic administration, respectively. The
method described by Ellman et al. (1961) evaluates the hydrolysis
of acetylcholine, and the AChE catalyzes the hydrolysis of ACh
much more rapidly than does BChE. The preferred substrate for
AChE is acetylcholine (ACh), while the preferred substrates for
BChE are butyrylcholine (BCh) and propionylcholine (PCh) (Tecles
and Ceron, 2001; Wilson and Philip, 2005; Wilson et al., 2001).
Ach is an essential player in the formation,maintenance and evo-
cation ofmemory processes. An excess level of Achwas shown to be
neurotoxic while the opposite is also true since low levels of Ach in
the synaptic junction may inﬂuence memory negatively (Soreq
and Seidman, 2001; Tõugu and Kesvatera, 1996). Based on our re-
sults we can suggest that the increase in AChE activity caused by
administrations of L-tyrosine may lead to a reduction of cholinergic
neurotransmission efﬁciency due to a decrease in acetylcholine lev-
els in the synaptic cleft, these ﬁnds can explain, at least in part, the
progressive cognitive impairment and other neurological dysfunc-
tions seen in patients affected by tyrosinemia type II. It has been
speculated that the degree of CNS involvement may be correlated
to abnormal high levels of plasma tyrosine (Mitchell et al., 2001).
The development of CNS occurs in phases, which follow a pre-
cise sequence (Morgane et al., 1992), we have chosen to study 10
and 30-day-old rats to track brain development. Slotkin et al.
(2005) identiﬁed a crucial phase of vulnerability of neuronal cells,
corresponding to peak periods of differentiation when metabolic
demands are especially high. The period of fastest dendritic out-
growth in rat brain is between 8 and 14 postnatal days, whereas
in the human is during the ﬁrst 2–3 years (Uylings, 2000).
L-Tyrosine can interfere in the development of the cholinergic
system through the dopaminergic system. Cholinergic cells in the
pons project to DA-rich cell body regions in the ventral tegmental
area and substantial nigra where they modulate the activity of
dopaminergic neurons and reward processing. The dopamine ter-
minal region of the nucleus accumbens contains a small but partic-
ularly important group of cholinergic interneurons, which have
extensive dendritic arbors that make synapses with a vast majority
of nucleus accumbens neurons and afferents. Together with acetyl-
choline input onto dopamine cell bodies, cholinergic systems couldserve a vital role in gating information ﬂow concerning the motiva-
tional value of stimuli through the mesolimbic system (Mark et al.,
2011). Thus, we believe that an increase in the tyrosine levels, con-
sequently increase the syntheses of catecholamines and interfere
in the development of the cholinergic system.
In the present study, the expression of ache were signiﬁcantly
decreased after chronic administration of L-tyrosine in striatum
and the AChE activity was increased, suggesting that this region
Fig. 2. Relative gene expression pattern of acetylcholinesterase in hippocampus,
striatum and cerebral cortex. Acute administration of L-tyrosine in (A) 10-day-old
rats and (B) 30-day-old rats, and (C) chronic administration. The semiquantitative
RT-PCR results were expressed as ache:b-actin optical density ratio with the
respective representative agarose gel band (mean ± SD of 5–6 animals per group).
Different from control, ⁄p < 0.05 (Student’s t test).
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tion machinery is continuously controlled by transcription/transla-
tion regulation, protein–protein interactions/modiﬁcations and a
metabolic network, together forming a system that allows the cell
to respond sensibly to the multiple signal molecules that exist in
its environment (Krishna et al., 2006). The phenomenon known
as negative feedback loop (Keseler et al., 2005; Salgado et al.,
2001), which is situated at the interface of metabolic and genetic
networks, could enlighten the concomitant increase of ACh hydro-
lysis and the decrease of ache levels in hippocampus after acute
administration of L-tyrosine. Grifman et al. (1997)) have also been
shown that the catalytic subunit of cAMP-dependent protein ki-
nase (PKA) can phosphorylate AChE at nonconsensus sites. We ob-
served that rat AChE presents a high predicted score of possible
phosphorylation sites: S-88 (PKA), T-280 (PKA) and S-593 (PKC)
according to analysis performed in NetPhosk, a kinase-speciﬁc pre-
diction of protein phosphorylation site tool. In this context, we
suggest that PKA phosphorylation performs the activation of AChE
activity after chronic administration. Therefore, PKA phosphoryla-
tion might be a decisive factor in the change of enzyme conforma-
tion, causing an increase in substrate–enzyme afﬁnity and enzyme
activity (Aldunate et al., 2004; Das et al., 2001; Melo et al., 2003).
A possible mechanism for phosphrorylation of PKA is the oxida-
tive stress since that it has involved in different capacitation-
related events, such as, the increase in cAMP levels and activation
of the cAMP/PKA-dependent pathway (Aitken et al., 1998; Herrero
et al., 2000; Leclerc et al., 1997). In this context, the study made by
Scaini et al. (2012)) demonstrated that the treatment with antiox-
idants was able to prevent the increased activity of AChE, but did
not change mRNA levels. Thus, we propose that AChE activity is
raised in the presence of ROS, since the treatment with antioxidant
revert this increase.
Many studies have been undertaken to deﬁne the localization of
acetylcholinesterase (AChE; EC 3.1.1.7) and its molecular forms in
brain (Brimijoin and Hammond, 1996; Koelle, 1963). Posttranscrip-
tionalmechanismsare thought to account formuchofAChE’s spatial
and temporal variation. Differentmechanismsmay operate in brain.
It remains possible that the local AChE content in each brain area re-
ﬂects the local rate of AChE production,which in turn reﬂects the lo-
cal abundance of AChEmRNA (Legay et al., 1993). Amore convincing
discrepancy between mRNA and enzyme levels is in the neostria-
tum, the brain region where AChE is overwhelmingly most abun-
dant. In announcing their cDNA clone for rat AChE, Legay et al.
(1993) noted that the striatum was relatively poor in AChE mRNA
as measured by Northern blotting. However, it is suggested that
the low overall level of striatal achemRNA reﬂects a scarcity of neu-
rons, expressing the transcript at high levels, and this may explain
the change in the striatum after administration of L-tyrosine.
However, the effect of administration of L-tyrosine in the hippo-
campus is not certainty known. But it is believed that the abun-
dance of the message largely parallels that of the protein itself,
the steady-state level of ache mRNA in many brain regions may
well reﬂect the rate of enzyme of biosynthesis.
The physiological consequence that could occur in our results,
in the acute and chronic administration, is a compensatory mech-
anism. This mechanism causes a down-regulation of ache mRNA
expression, which in turn reﬂects in the rate of AChE production,
thus the enzyme activity gets normal and the cholinergics trans-
missions do not cause undesirable effects (Hammond et al., 1994).5. Conclusions
Results demonstrated a marked increase in AChE activity in all
evaluated brain areas after administration of L-tyrosine. We sug-
gest that neurological sequelae in tyrosine.
1374 G.K. Ferreira et al. / Neurochemistry International 61 (2012) 1370–1374Tirosinemic patients is associated with decreased levels of Ach
in the synaptic cleft caused by increased activity of AChE, thus con-
tributing to progressive cognitive impairment and other neurolog-
ical dysfunctions seen in patients affected by tyrosinemia type II.
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